2024/10/12 更新

写真a

ウエキ ヒデオ
植木 英雄
UEKI Hideo
所属
総合技術部 技術専門職員
職名
技術専門職員
外部リンク

研究分野

  • ライフサイエンス / 泌尿器科学

 

論文

  • The Necroptotic Process-Related Signature Predicts Immune Infiltration and Drug Sensitivity in Kidney Renal Papillary Cell Carcinoma. 国際誌

    Wenfeng Lin, Ruizhi Xue, Hideo Ueki, Peng Huang

    Current cancer drug targets   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: It remains controversial whether the current subtypes of kidney renal papillary cell carcinoma (KIRP) can be used to predict the prognosis independently. OBJECTIVE: This observational study aimed to identify a risk signature based on necroptotic pro-cess-related genes (NPRGs) in KIRP. METHODS: In the training cohort, LASSO regression was applied to construct the risk signature from 158 NPRGs, followed by the analysis of Overall Survival (OS) using the Kaplan-Meier method. The signature accuracy was evaluated by the Receiver Operating Characteristic (ROC) curve, which was further validated by the test cohort. Wilcoxon test was used to compare the expressions of immune-related genes, neoantigen genes, and immune infiltration between differ-ent risk groups, while the correlation test was performed between NPRGs expressions and drug sensitivity. Gene set enrichment analysis was used to investigate the NPRGs' signature's biologi-cal functions. RESULTS: We finally screened out 4-NPRGs (BIRC3, CAMK2B, PYGM, and TRADD) for con-structing the risk signature with the area under the ROC curve (AUC) reaching about 0.8. The risk score could be used as an independent OS predictor. Consistent with the enriched signaling, the NPRGs signature was found to be closely associated with neoantigen, immune cell infiltration, and immune-related functions. Based on NPRGs expressions, we also predicted multiple drugs potentially sensitive or resistant to treatment. CONCLUSION: The novel 4-NPRGs risk signature can predict the prognosis, immune infiltration, and therapeutic sensitivity of KIRP.

    DOI: 10.2174/0115680096286503240321040556

    PubMed

    researchmap

  • Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma. 国際誌

    Jun Matsumoto, Anzu Nishimoto, Shogo Watari, Hideo Ueki, Shoya Shiromizu, Naohiro Iwata, Tatsuaki Takeda, Soichiro Ushio, Makoto Kajizono, Masachika Fujiyoshi, Toshihiro Koyama, Motoo Araki, Koichiro Wada, Yoshito Zamami, Yasutomo Nasu, Noritaka Ariyoshi

    Molecular and cellular biochemistry   478 ( 8 )   1779 - 1790   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    UDP-glucuronosyltransferase (UGT) metabolizes a number of endogenous and exogenous substrates. Renal cells express high amounts of UGT; however, the significance of UGT in patients with renal cell carcinoma (RCC) remains unknown. In this study, we profile the mRNA expression of UGT subtypes (UGT1A6, UGT1A9, and UGT2B7) and their genetic variants in the kidney tissue of 125 Japanese patients with RCC (Okayama University Hospital, Japan). In addition, we elucidate the association between the UGT variants and UGT mRNA expression levels and clinical outcomes in these patients. The three representative genetic variants, namely, UGT1A6 541A > G, UGT1A9 i399C > T, and UGT2B7-161C > T, were genotyped, and their mRNA expression levels in each tissue were determined. We found that the mRNA expression of the three UGTs (UGT1A6, UGT1A9, and UGT2B7) are significantly downregulated in RCC tissues. Moreover, in patients with RCC, the UGT2B7-161C > T variant and high UGT2B7 mRNA expression are significantly correlated with preferable cancer-specific survival (CSS) and overall survival (OS), respectively. As such, the UGT2B7-161C > T variant and UGT2B7 mRNA expression level were identified as significant independent prognostic factors of CSS and CSS/OS, respectively. Taken together, these findings indicate that UGT2B7 has a role in RCC progression and may, therefore, represent a potential prognostic biomarker for patients with RCC.

    DOI: 10.1007/s11010-022-04637-4

    PubMed

    researchmap

  • Identification of MICALL2 as a Novel Prognostic Biomarker Correlating with Inflammation and T Cell Exhaustion of Kidney Renal Clear Cell Carcinoma

    Wenfeng Lin, Wenwei Chen, Jisheng Zhong, Hideo Ueki, Abai Xu, Masami Watanabe, Motoo Araki, Chunxiao Liu, Yasutomo Nasu, Peng Huang

    JOURNAL OF CANCER   13 ( 3 )   1214 - 1228   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:IVYSPRING INT PUBL  

    Purpose: The interplay of inflammation and immunity affects all stages from tumorigenesis to progression, and even tumor response to therapy. A growing interest has been attracted from the biological function of MICALL2 to its effects on tumor progression. This study was designed to verify whether MICALL2 could be a prognostic biomarker to predict kidney renal clear cell carcinoma (KIRC) progression, inflammation, and immune infiltration within tumor microenvironment (TME). Methods: We firstly analyzed MICALL2 expressions across 33 cancer types from the UCSC Xena database and verified its expression in KIRC through GEPIA platform and GEO datasets. The clinicopathological characteristics were further analyzed based on the median expression. Kaplan-Meier method, univariate and multivariate analyses were applied to compare survival outcomes. ESTIMATE and CIBERSORT algorithms were performed to assess immune infiltration, and a co-expression analysis was conducted to evaluate the correlation between MICALL2 and immunoregulatory genes. Enrichment analysis was finally performed to explore the biological significance of MICALL2. Results: MICALL2 was highly expressed in 16 types of cancers compared with normal tissues. MICALL2 expression increased with advanced clinicopathological parameters and was an independent predictor for poor prognosis in KIRC. Moreover, MICALL2 closely correlated with inflammation-promoting signatures and immune infiltration including T cell exhaustion markers. Consistently, MICALL2 involved in the regulation of signaling pathways associated with tumor immunity, tumor progression, and impaired metabolic activities. Conclusion: MICALL2 can function as a prognostic biomarker mediating inflammation, immune infiltration, and T cell exhaustion within the microenvironment of KIRC.

    DOI: 10.7150/jca.66922

    Web of Science

    researchmap

  • Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma. 査読 国際誌

    Jun Matsumoto, Yumi Kotera, Shogo Watari, Koichi Takeuchi, Hideo Ueki, Toshihiro Koyama, Koichiro Wada, Masachika Fujiyoshi, Yasutomo Nasu, Noritaka Ariyoshi

    Anticancer research   41 ( 5 )   2511 - 2521   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. RESULTS: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. CONCLUSION: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

    DOI: 10.21873/anticanres.15029

    PubMed

    researchmap

  • Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy. 国際誌

    Jingkai Sun, Wenfeng Lin, Chaoming Li, Hideo Ueki, Ruizhi Xue, Takuya Sadahira, Hao Hu, Koichiro Wada, Na Li, Chunxiao Liu, Motoo Araki, Abai Xu, Peng Huang

    American journal of cancer research   11 ( 9 )   4528 - 4540   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Posaconazole (POS) is a novel antifungal agent, which has been repurposed as an anti-tumor drug for its potential inhibition of Hedgehog signaling pathway. Hedgehog pathway is reported to be abnormally activated in embryonal rhabdomyosarcoma (ERMS), this study aimed to reveal whether POS could inhibit Hedgehog signaling pathway in ERMS. Following POS treatment, XTT viability assay was used to determine the cell proliferation of ERMS cell lines. Protein changes related to Hedgehog signaling, cell cycle and autophagy were detected by Western blot. The cell cycle distribution was analyzed by flow cytometry. Moreover, a subcutaneous tumor mouse model of ERMS was established to assess the anti-tumor effect of POS. POS was found to inhibit tumor progression by inducing G0/G1 arrest and autophagy of RD, RMS-YM, and KYM-1 cells dose-dependently. Western blot demonstrated that POS downregulated the expressions of SMO, Gli1, c-Myc, CDK4, and CDK6, while upregulated the expressions of autophagy-related proteins. Immunofluorescence microscopy revealed a significant increase of LC3B puncta in POS-treated ERMS cells. Furthermore, POS treatment led to a significant inhibition of tumor growth in mice bearing ERMS. Our findings could provide a theoretical basis and have important clinical implications in developing POS as a promising agent against ERMS by targeting Hedgehog pathway.

    PubMed

    researchmap

▼全件表示

MISC

  • Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging

    H. Kaku, H. Ueki, Y. Ariyoshi, S. Li, P. Huang, Y. Nasu, H. Kumon, M. Watanabe

    HUMAN GENE THERAPY   24 ( 12 )   A154 - A154   2013年12月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:MARY ANN LIEBERT, INC  

    Web of Science

    researchmap

  • 植物シスタチン遺伝子導入による耐虫性ダイズの作出

    山田聖, 植木英雄, 喜多洋一, 西沢けいと, 黒田昌治, 与座宏一, 北山雅彦, 石本政男

    日本植物生理学会年会要旨集   46th ( 0 )   227 - 491   2005年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本植物生理学会  

    DOI: 10.14841/jspp.2005.0.491.0

    CiNii Article

    J-GLOBAL

    researchmap

講演・口頭発表等

  • ダイズシストセンチュウ抵抗性遺伝子型を判別する分子マーカーの開発

    植木 英雄

    日本育種学会 第105回講演会  2004年 

     詳細を見る

  • サツマイモにおけるレトロトランスポソンLTR配列の解析

    植木 英雄

    日本育種学会 第100回講演会  2001年 

     詳細を見る

産業財産権

  • REIC/Dkk−3タンパク質の部分領域ポリペプチド

    公文 裕巳, 渡部 昌実, 二見 淳一郎, 藤井 康之, 植木 英雄, 落合 和彦

     詳細を見る

    出願人:国立大学法人 岡山大学, 桃太郎源株式会社

    出願番号:特願2012-522733  出願日:2011年7月1日

    公開番号:WO2012-002582  公開日:2012年1月5日

    特許番号/登録番号:特許第5936129号  発行日:2016年5月20日

    J-GLOBAL

    researchmap

共同研究・競争的資金等の研究

  • Oncolytic virus の多元的制癌性の解明と革新的癌治療への展開

    研究課題/領域番号:22K09526  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    植木 英雄

      詳細を見る

    配分額:3900000円 ( 直接経費:3000000円 、 間接経費:900000円 )

    researchmap

  • 骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索

    研究課題/領域番号:21K09371  2021年04月 - 2024年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    黄 鵬

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    癌の研究開発において、癌免疫逃避機構に関する最近の注目すべき研究として、骨髄由来免疫抑制細胞(MDSC: myeloid-derived suppresser cell)が、癌に対する免疫監視機構や抗腫瘍免疫を負に制御して癌の悪性進展の中心的役割を担っていることが明らかにされつつある。本申請研究では、骨髄由来免疫抑制細胞の抗癌免疫逃避機構の解明に基づく革新的癌創薬の探索を目指している。本年度は、
    ①前立腺がん担癌マウスより末梢血を採収後FACS AriaでMDSSC細胞を分離し、MDSC細胞の表面マーカーの確認を行った。分離したMDSC細胞に対するREIC/Dkk-3タンバク質の抑制効果の観点から解析した。さらに、Ad-REICの抗癌作用に基づく免疫逃避応答に関する機序を解明し、その有効性を検証した。
    ②分離したMDSC細胞にREIC/Dkk-3タンパク質を作用させ、1分、30分、1時間、6時間、24時間後細胞内タンパク質を抽出し、または特異的siRNAによりノックダウンさせ、遺伝子-タンパク質発現変動をマイクロアレイやタンパク質抗体アレイ等により解析した。また、Western blot法により関連したパスウェイ内の各種タンパク質およびそのリン酸化の動態を実験した。
    ③細胞核内の標的遺伝子群(転写されるタンパク質群)の同定を行い、REIC/Dkk-3とMDSC細胞膜上での結合分子・受容体の同定解析を行った。

    researchmap

  • 新規の癌抗原CD147を標的とする適応免疫最適化と尿路性器腫瘍での応用展開

    2018年04月 - 2022年03月

    日本学術振興会  科学研究費/基盤研究(B) 

    那須 保友

      詳細を見る

    資金種別:競争的資金

    researchmap

  • 制限増殖型アデノウィルスを用いた次世代遺伝子治療の基盤研究

    2018年04月 - 2021年03月

    日本学術振興会  科学研究費/基盤研究(C) 

    小林 泰之

      詳細を見る

    資金種別:競争的資金

    researchmap

  • REIC/Dkk-3遺伝子による前立腺細胞増殖制御機構に関する研究

    2018年04月 - 2021年03月

    日本学術振興会  科学研究費/基盤研究(C) 

    高本 篤

      詳細を見る

    資金種別:競争的資金

    researchmap

▼全件表示